We are pleased to be part of the National Institute for Health Research Clinical Research Network (NIHR CRN) for Wessex.  This means we are part of a network of GP partnerships who host medical research on a regular basis. Findings from research studies help all GPs, nurses and other health professionals provide the most appropriate and up-to-date care. Patients registered with us have an opportunity to help shape the future of health care by taking part in research projects.

As a member of the Clinical Research Network, we will from time to time invite patients to take part in research studies.  You will always receive clear information about what taking part in any research study would involve. You will have the opportunity to ask questions and obtain further details about the study with no obligation to take part.

There are various ways a patient can become involved in studies at Living Well and requirements vary from study to study and if you choose to take part, this could include:

  • Filling in a questionnaire

  • Talking to a researcher about your views/symptoms

  • Letting the researcher look at your medical notes

  • Trying a new treatment, therapy or device

  • Experiencing new combinations or timings of treatments

  • Providing samples for testing (blood, urine, breath etc.)

You may be sent information through the post, or read information about a current study in the patient waiting room or on the surgery website and wish to take part or your GP/nurse may discuss the study in a consultation where appropriate.

Participation in any research project is entirely voluntary and you can withdraw at any time throughout any study. Declining or withdrawing from any study will not affect your medical care in any way.

More information about some of our active research projects can be found below.

RCGP Research & Surveillance

This practice is one of over 1900 practices in England and Wales contributing pseudonymised data for national research and surveillance. These data enable continuous monitoring of infections and diseases in the community and is used in ethically approved research. The Oxford RCGP RSC is the main source of information for Public Health England (PHE) and helps with prediction and management of flu outbreaks and pandemics.

Providing pseudonymised data does not affect patients, their care or privacy, however if you no longer wish to allow your information to be used, please submit an Admin eConsult.

The pseudonymised data, extracted by information service providers, Wellbeing Software and Egton Medical Information Systems (EMIS), are processed within the private and secure network of the Clinical Informatics and Health Outcomes Research Group at University of Oxford under a formal data sharing agreement. The pseudonymised data may be linked with other NHS data for analysis, including hospital episode statistics.

For further information please visit http://www.rcgp.org.uk/rsc or contact:

Prof Simon de Lusignan (Data Controller)                                                                  Oxford RCGP RSC Practice Liaison Team
MedicalDirectorRSC@rcgp.org.uk                                                                                Practiceenquiries@phc.ox.ac.uk

This research study aims to find out whether people with chronic kidney disease (CKD) should take a daily low-dose aspirin tablet to reduce the risk of a heart attack or stroke.

We are inviting all potentially suitable patients to take part. This includes people aged 18 or over who have had blood or urine tests that indicate they have CKD.

CKD has 5 different stages. Stage 1 technically is normal however, as medicine is progressing we are picking up and defining some very early diagnoses before they make anyone unwell. Some patients may be receiving the invite as early as stage 1 as they fulfil the extensive criteria of this study. If you receive a letter about this study we really do not want you to worry but to understand that participation is entirely voluntary to this study and regardless of participation or the CKD stage you will be monitored as current guidance recommends. Please look out for emails and texts inviting you for annual blood tests, blood pressure and urine tests.

There is some excellent information for further advice available at the Kidney Information website.

If you have any further concerns, please do not hesitate to drop us an eConsult and if you mark this specifically for the attention of Dr Pritti Aggarwal the Principal Investigator for the Living Well Partnership, she will get back to you in due course.

 Have PCOS and trying for a baby? Join our LOCI research trial!

We are looking for women with polycystic ovary syndrome (PCOS) who are trying to conceive, to take part in a new clinical trial, called ‘LOCI’. LOCI is investigating the effectiveness of two different drugs (letrozole and clomifene) on fertility, pregnancy and successful births. Both of these drugs aim to induce or ‘switch on’ ovulation, which is often disrupted in women with PCOS. Improved ovulation should increase the chances of becoming pregnant. Clinicians and researchers do not yet know which should be the first-line medication.

Women in the study will take part in up to 6 treatment cycles where letrozole or clomifene is taken with or without (placebo) the drug metformin. These drugs are already widely used and considered safe, but the results of LOCI will provide important insights on which combination of drugs works best – something which is still unknown. By taking part in this trial you will be helping our research team move science forwards and giving many women with PCOS a better chance of getting pregnant and giving birth in future. During your involvement, you will be monitored by your clinical team and treated with respect and dignity throughout. Your data will be kept confidential at all times and you are free to leave the study at any time.

We welcome women of any ethnicity or background to take part. If language or access barriers are an issue, please let us know as we would like to facilitate your participation wherever possible e.g. providing an interpreter to help. To find out more you can check our website and/or contact us


Q1. I don’t have a formal diagnosis of PCOS, can I still take part?

In order to take part in this trial you must have a formal diagnosis of PCOS and be under the care of a fertility team. This is to ensure we are targeting the correct group of women and that you have the right clinical care in place. If you are having difficulty conceiving and think that you may have PCOS, you should see your GP for a referral to a fertility team. They should perform the necessary investigations to confirm or exclude PCOS.

Q2. Are there any specific criteria to be able to take part?

Yes, in order to be able to take part in the trial you must meet the following critera:

– Formal diagnosis of PCOS and evidence of anovulation (not releasing an egg each month)
– Presentation with infertility or wishing to conceive
– Male partner (or donor sperm) with normal sperm count and motility

– Willing and able to give informed consent

Q3. If I meet the requirements, are there any specific criteria which would mean I cannot take part?

The following list is our study exclusion criteria:

  • If you are aged => 18 to <=42
  • If your Body Mass Index (BMI) is greater than 35 kg/m²
  • If you have had more than six ovulation induction treatments (cycles) with either letrozole or clomifene in the previous 12 months – If you are wishing to continue on metformin treatment for ovulation induction or for other indications- If you wish for alternative methods of ovulation induction
  • If you have any contraindications to letrozole, clomifene, metformin use and/or pregnancy
  • Previously participated in the LOCI trial

Q4. Are the drugs letrozole, clomifene and metformin new and are they safe?

The LOCI trial has been reviewed by the West Midlands—Edgbaston Research Ethics Committee. Additionally, the study will be supervised on a regular basis by an independent Data Monitoring and Ethics Committee (DMEC) and Trial Steering Committee (TSC) to ensure the safety of all participants in the study.

The doctors and nurses/midwives caring for you will not receive any payments for recruiting women into the study. Our study participants will not be paid either, but they will be greatly appreciated, and they will be important in finding out more about how to enhance ovulation induction in women with PCOS and infertility.

All of these drugs are already widely in use, so they have been tested for safety in humans. As with any drug there may be side effects, so feel free to ask your doctor or our team about what these might be before taking part.

  • Metformin is frequently used in type 2 diabetes treatment, however it is also commonly used in PCOS to regulate periods and improve fertility in women with PCOS.
  • Clomifene is used to treat infertility in women who do not ovulate, including those with PCOS.
  • Letrovole is used in the treatment in some kinds of breast cancer (those that respond to hormones), however it is also used to improve ovulation induction and there is evidence to suggest it may produce less side effects than clomifene.

Q5. I don’t live in Birmingham, can I still take part?

This study is being conducted across the UK. We aim to have approximately 45 hospitals recruiting for this study. You can contact the trials unit to find out where your local recruiting hospital is.

Q6: I take medications for other health conditions. Is this a problem or can I still take part?

This will depend on the type of medication you are on. Please get in touch with by email and we can discuss your individual circumstances. If you are already taking certain medication for PCOS, such as Metformin, these would have to be stopped for 14 days weeks before you could take part in the trial.

Q7. How do you decide which drug to give me or can I choose this myself?

Our research study is a randomised clinical trial, which means that we ‘randomly’ assign the drug choice to the women who are taking part in the study at the very beginning. We do this in a way that tries to ensure that each of the four experimental groups [letrozole or clomifene with or without the drug metformin, see table below] is roughly similar e.g. similar numbers of women in each group, roughly the same age range, mix of ethnicities etc. This enables us to more fairly look at the outcomes of the study and its makes the results that we get at the end more reliable.

Each volunteer will get assigned to one of the following groups:

Group 1: Letrozole and no metformin. Group 3:Clomifene and no metformin.
Group 2: Letrozole and metformin. Group 4:Clomifene and metformin.

Q8. What if there is a problem?

If you take part in the study, then you will retain the same legal rights as any other patient within the National Health Service. If you are not satisfied with any aspect of the way in which you have been approached or treated during the course of our study, then please speak first to the researchers at your hospital.


The ELSA Study is screening children for type 1 diabetes.

Children aged 3-13 years can have a simple finger stick blood test to find out their risk of developing type 1 diabetes in the future.

Visit ELSA study for more details.

COVID-19 has affected the lives of everybody within the UK and the rest of the world. Finding safe and effective treatments has been the drive of our researchers at the University of Oxford and right now, you have anopportunity to help.

PANORAMIC is a national priority trial to find treatments for COVID-19.

We are looking for volunteers aged 50 or over, or aged 18 or over with an underlying health condition.

To be eligible to take part, you must have had a positive COVID-19 test result and be unwell with COVID-19 symptoms which started within the last 5 days.

Please help us fight COVID-19 by visiting Panoramictrial.